Xceleron and JCL Bioassay Partner in Early-Stage Clinical Investigations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Xceleron and JCL Bioassay Partner in Early-Stage Clinical Investigations



Xceleron, a provider of bioanalytical accelerator mass spectrometry (AMS) services for accelerated early drug development, has entered into a partnership with JCL Bioassay, a Japanese CRO and provider of bioassay services for preclinical and clinical developments. The partnership seeks to offer drug developers access to a range of sensitive and robust analytical platforms for early clinical development across Asia, Europe, and North America.

"This partnership emphasizes the crucial role of contemporary analytical platforms in driving down the cost of drug development. Whether in Phase 0 or enriched Phase I, we can confidently provide critical pharmacokinetic and pharmacodynamic information before Phase II," said Dr Michael Butler, CEO of Xceleron, in a press statement.

Over the years, Phase 0 and enriched Phase 1 studies have been used successfully in to investigate a range of developmental endpoints such as the presence of drug at tissues or cells of interest, absolute bioavailability, and human metabolism. These studies when conducted early in drug development allow confident decision-making that offers a cost-effective alternative when compared to later stages of clinical development.

More than 100 analytical methods for Phase 0 and enriched Phase I investigations have been developed between Xceleron and JCL Bioassay. Both companies recently built laboratories that are equipped and staffed specifically for the purpose of conducting ultra-low level analyses under good laboratory practice (GLP) and good clinical practice (GCP) conditions. This partnership will provide access to clinical design expertise as well as appropriate analytical platforms for the purpose of early clinical investigation.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here